Lobe Sciences Ltd.
LOBEF · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.01 | 0.00 |
| FCF Yield | -17.76% | -72.15% | -341.28% | -763.30% |
| EV / EBITDA | -1.00 | -0.58 | 0.03 | 0.08 |
| Quality | ||||
| ROIC | 155.90% | -2,035.76% | -922.84% | -54.03% |
| Gross Margin | 98.71% | 97.14% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.10 | 0.37 | 0.22 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 73.10% | 37.06% | 45.79% | -312.08% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | -0.04 | 0.22 | 0.19 |
| Interest Coverage | -11.34 | -86.93 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.41 | 0.00 | 0.00 |
| Cash Conversion Cycle | -162,724.91 | -28,950.90 | 0.00 | 0.00 |